Revised standards for four ingredients widely used in prescription and over-the-counter drugs announced

NewsGuard 100/100 Score

Standards revision will apply to four common pharmaceutical excipients, will be legally enforceable for US-marketed products

To further protect patients from adulterated medicines, the U.S. Pharmacopeial Convention (USP) today announced revised standards for four ingredients widely used in prescription and over-the-counter drugs. The standards, posted on the USP Web site, include new tests for identifying two harmful and potentially deadly contaminants in the four pharmaceutical excipients-inactive ingredients common in medicines for purposes including sweetening agents and solvents.

USP is a nonprofit, scientific organization that sets legally recognized standards designating the identity, quality, purity, strength and consistency of prescription and over-the-counter medications and their ingredients in the United States. These standards are enforced by the U.S. Food and Drug Administration (FDA). The revisions respond to a request from FDA to revise the USP Propylene Glycol and Sorbitol Solution standards to include limits for diethylene glycol (DEG) to help prevent future episodes of pharmaceutical adulterations with this poisonous chemical. DEG is commonly used in antifreeze and has no legitimate place in medicines. Adulterations of cough syrups and other products with DEG have occurred many times and in many countries, including a tragic episode between November 2008 and January 2009 in which 84 children in Nigeria died after ingesting teething syrup contaminated with DEG. A similar episode occurred in July 2009 in Bangladesh, killing at least 24 children.

The revisions come after USP recently updated its standard for Glycerin, another pharmaceutical excipient. Consistent with the Glycerin revision, the updated "high priority" standards for the pharmaceutical excipients will help ensure the absence of DEG and ethylene glycol (EG), another poisonous chemical, each at a level of not more than 0.10 percent. The standards will become official February 1, 2010, allowing for a 12-week implementation period. All manufacturers using these pharmaceutical excipients in their U.S.-marketed products will be required to comply with these new standards once official.

"The adulteration of drugs and their ingredients is a critical public health issue," said Susan de Mars, USP chief documentary standards officer. "As recently as a few months ago, this was tragically illustrated in separate instances in Bangladesh and Nigeria. USP, in close collaboration with FDA, manufacturers, and other national and international parties, is addressing this by updating our standards for 'at risk' products. The unfortunate reality of economic incentives to counterfeit medicines makes this necessary."

The revision effort additionally proposed new standards for USP Sorbitol Sorbitan Solution and Noncrystallizing Sorbitol Solution. The four revised monograph standards were originally posted on the USP Web site on July 1 to allow manufacturers, regulators and all other interested parties until August 14 to review the proposed changes-found in the "Identification" sections of the monographs-and provide informal comment on USP's approach prior to its formal posting via USP's Revision Bulletin process. USP also held three open Web meetings to communicate these proposed revisions to stakeholders.

In addition to the written standards, USP has developed physical reference materials for the pharmaceutical excipients as well as impurities reference materials for DEG and EG. These physical materials are used by manufacturers and regulators to ensure a substance meets the USP written standards.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study finds erectile dysfunction drugs linked to lower Alzheimer's risk